A growing body of clinical trials support the hypothesis that blocking these cytokines could partly relieve inflammatory symptoms of AOSD and reduce disease severity, such as TNF-α blockers and IL-1β and IL-6 antagonists [8, 14, 15]. Here, TNF is linked to adult-onset Still disease.